Summary Fifty-seven patients with metastatic melanoma were treated with interleukin 2 (IL-2) 7.8 MIU m-day as a continuous infusion for 4 days combined with interferon a (IFN-a) 6 MIU m day-' subcutaneously on days I and 4. The cycle was repeated every 2 weeks for a maximum number of 13 cycles. Of the 51 evaluable patients, one (2%) achieved a complete and seven (14%) a partial response (total response rate 16%: C1 7-29%). Median time to progression and median survival were 2.5 and 11.3 months respectively. This regimen of IL-2 and IFN-a appeared to be only moderately active.
Immunotherapy with recombinant interleukin 2 (IL-2) has been reported to yield a 5-27% response rate in metastatic melanoma (Rosenberg et al., 1989a (Rosenberg et al., , 1993 Parkinson et al., 1990; Whitehead et al., 1991; Sparano et al., 1993) . Interferon x (IFN-() alone in this group of patients has shown response rates of 12-22% (Robinson et al., 1986; Kirkwood, 1991) .
Based on the synergistic activity of IL-2 and IFN-a in preclinical experiments (Brunda et al., 1987; Cameron et al., 1988; ligo et al., 1988) and on the encouraging results of early clinical trials with this combination (Budd et al., 1989; Lee et al., 1989; Rosenberg et al., 1989b) , we decided to perform a phase II study. Here, we report the final analysis after a median follow-up period of 10.5 months (range 1.1 -47+ months). and toxicity. The patient characteristics are shown in Table I The median duration of response was 8.2 months (range 4.5-39+ months). For all 51 patients the median time to progression was 2.5 months (range 0.5-39+ months). Time to progression for responding patients was 8.2 months (range 4.5-39+ months), for patients with stable disease 3.6 months (range 1.7-9.4 months) and for progressive disease patients 1.2 months (range 0.5-2.0 months). The median survival of all patients was 11.3 months (Figure 1) , and of the responding patients 20.2 months. Toxicity An overview of the observed toxicity is presented in Table H . Frequently occurring side-effects were fever, skin rash, nausea, vomiting, diarrhoea and malaise. Two-thirds of patients had tachycardia and hypotension, mostly of mild to moderate grade. Life-threatening hypotension requiring vasopressors occurred in three patients, who were taken off study (see above). One patient developed ventricular extrasystoles and another patient atrial fibrillation. In a minority of patients neurological abnormalities and mental disturbances were seen, Neurotoxicity included aphsia, peripheral neuropathy, somnolence, confusion and agitation.
Two patients required dose reductions because of adverse events, and in eight patients short interruption of treatment was needed. Not toxic death occurred and all toxicties resolved after cessation of immunotherapy. Chronic cumulative fatigue occurred after about 3 months of treatment. Consequently, only two patients received more than 13 cycles.
The most frequent manifestation of haematological toxicity was anaemia (71%). Thrombocytopenia was seen in 18% of the patients. Moderate and reversible increases in serum creatinine and bilirubin occurred in a minority of patients.
In this study the combined use of IL-2 and IFN-z in the treatment of metastatic melanoma resulted in a 16% res- Response rates of 21-44% have been reported in some studies using the combination of both cytokines (Lee et al., 1989; Rosenberg et al., 1989b; Budd et al., 1992) . However, low response rates of 10% or less were observed by others (Olham et al., 1992; Dillman et al., 1993; Sparano et al., 1993) . The median response duration in these trials varied between 2 and 11 months, and the median survival was approximately 10 months (Lee et al., 1989; Rosenberg et al., 1989b; Oldham et al., 1992; Dillman et al., 1993; Sparano et al., 1993) . We achieved similar results. We failed to confirm the ability of IFN-a to augment the effect of IL-2. This may have been due to suboptimal dose and schedule. Our patients received moderate doses of IL-2. In animal studies the efficacy of IL-2 is dose dependent without reaching a plateau below the maximum tolerated dose (Mule et al., 1984) . However, in trials using high-dose IL-2 (18 MIU m2 day-') given by continuous infusion in patients with metastatic melanoma inferior response rates were reported (Oldham et al., 1992; DilIman et al., 1993 ). An NCI Surgery Branch Study, administering high-dose bolus IL-2 (> 30 MIU m-2 day-') and IFN-a found the highest response rates (Rosenberg et al., 1989b) . On the other hand, the Extramural IL-2 Working Group, using identical dose, schedule and patient selection criteria, did not observe any evidence of enhanced response with the IL-2/IFN-a combination (Sparano et al., 1993) . In summary, a dose-response effect for IL-2 in the treatment of metastatic melanoma is not clear.
The side-effects we observed were of similar incidence and severity as reported previously (Lee , 1993) . Toxicity was manageable and patients tolerated the therapeutic regimen relatively well. However, cumulative fatigue made it impossible to give patients more than 13 cycles of therapy.
In conclusion, combined therapy with IL-2 and IFN-a in the described regimen has only moderate activity in the treatment of patients with metastatic melanoma. Further clinical trials have to be designed to improve therapeutic results.
